June 13, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
CHICAGO — In patients being treated for hypertension, those taking a GLP-1 receptor agonist had higher rates of hypotensive events compared with those not taking one, researchers reported at ENDO 2026. “I began to notice multiple patients in clinic who were started on GLP-1s (by me and others) who were complaining of lightheadedness, dizziness and fainting. They had low blood pressure on my
Questo articolo non è idoneo per il formato TL;DR di Warptech Tech News. È un articolo medico-sanitario (studi su GLP-1 e ipotensione) senza nessuna implicazione per manager IT, CTO, o decisioni tech/business. La struttura richiesta (Frase 2: "perché conta per un manager tech") non ha spunti pertinenti. Se arriva in coda editoriale, consiglio **reject** — oltre scope della testata.
June 13, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Patients with migraine who began using GLP-1 receptor agonists for obesity did not experience any significant changes in headache…

NEW ORLEANS — Individuals with obesity and autoimmune diseases who use a GLP-1 receptor agonist may have lower risk for…

GLP-1s may prevent adverse outcomes in patients with peripheral artery disease and diabetes, according to data published in the…

GLP-1 receptor agonists were associated with a higher risk for eye complications vs. other diabetes medications, two studies…

Data collected from a number of clinical trials found that despite recent “buzz,” there is no significant link between GLP-1…

Although nearly a third of individuals with obesity who use GLP-1 receptor agonists experience constipation, the risk for…